This Centre - led by Professor Andrew Lister - has a long and distinguished history in haemato-oncology, urological and paediatric malignancies, having led several pivotal trials in the treatment of these cancers.  

Facilities include:

• High throughput sequencing (Roche 454)
• Full Affymetrix microarray support for expression profiling and SNP genotyping with an embedded bioinformatics group
• Real-time PCR facilities for expression analysis
• Molecular cytogenetics facilities.

As part of the Cancer Services Directorate of Barts and The London NHS trust, many of the Centre's staff provide clinical care at St Bartholomew's Hospital, with particular expertise in the treatment of adult and childhood leukaemia, lymphomas and other haematological cancer, and for testes, prostrate and other urological tumours.

Research units and groups
There are four main research units within the Centre, which carry out independent and interrelated research both in the clinic and the laboratory.

• Clinical and Applied Medical Oncology Group
  Prof Andrew Lister, Dr Silvia Montoto, Professor Ama Rohatiner and Dr Jude Fitzgibbon
  Aims to characterise the molecular signature of lymphomas to identify recurrent genomic and expression changes within these lymphomas to guide treatment selection.
• Cancer Genomics Group
  Prof Bryan Young and Dr Manoj Raghavan
  Aims to understand the key genetic events in malignant transformation through molecular cytogenetics, SNP genotyping approaches and high throughput genomic sequencing. Key genetic events in the development of Leukaemia are being uncovered by the application of genomic strategies.
• Cancer Immunotherapy Group
  Prof John Gribben, Prof Finbarr Cotter and Dr David Taussig
  Aims to develop immunotherapy approaches for the treatment of cancer, including stem cell transplantation; and to identify tumour antigens with particular emphasis on B cell malignancies.
• Clinical Cancer Pharmacology Unit
  Dr Simon Joel
  This Unit conducts pharmacodynamic and pharmacokinetic studies of cytotoxic agents against a background of clinical trials. There is particular interest in therapeutic drug monitoring and factors that influence drug handling, the development of novel agents in haematological malignancies, and an increasing focus on interactions between new agents and conventional DNA damaging drugs. The a im is to develop and test new agents in the laboratory and in clinical trials and to optimise the way in which established chemotherapy drugs are used through a better understanding of their molecular and clinical pharmacology.